Back to top

Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs

Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Bilio...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Silence Therapeutics PLC Sponsored ADR (SLN)